Global Structural Heart Devices Market Size study, by Type (Surgical Aortic Valve Replacement, Transcatheter Aortic Valve Replacement, Mitral Repair, Left Atrial Appendage Closure) and Regional Forecasts 2022-2028

Global Structural Heart Devices Market Size study, by Type (Surgical Aortic Valve Replacement, Transcatheter Aortic Valve Replacement, Mitral Repair, Left Atrial Appendage Closure) and Regional Forecasts 2022-2028

Global Structural Heart Devices Market is valued approximately USD 5.87 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 9.15% over the forecast period 2022-2028. The high prevalence of the target condition is the primary market driver. Almost 60 million people in the United States have structural heart abnormalities. This accounts for around 20% to 25% of the entire population. This demonstrates the broad range of devices used to treat structural heart abnormalities. Structural heart disease (SHD) refers to a broad category of percutaneous therapies for patients with both acquired and congenital heart disease (CHD) that involve functional and structural abnormalities of the cardiac chambers, proximal great arteries, and heart valves. According to The Numerous Foundation, one out of every 100 newborns have congenital heart abnormalities that range from mild to severe. According to Micro Interventional Devices, Inc., in 2019 structural cardiac problems afflict roughly 60 million people in the United States, or 20 to 50% of the elderly. The payment situation is projected to improve, making operations like TAVR (Transcatheter Aortic Valve Replacement) cheaper. As the target demographic ages, the Centers for Medicare and Medicaid Services will reimburse their medical expenses (CMS). It will reduce the burden of healthcare spending, encouraging more individuals to seek treatment. This has a good influence on operations like Left Atrial Appendage Closure (LAAC), which are useful for lowering the risk of stroke. However, strict compliance regulations impedes the growth of the market over the forecast period of 2022-2028.

The key regions considered for the Global Structural Heart Devices Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America emerged as the market leader. The primary reason for this domination is a high desire for least intrusive treatments. Since 2006, the rate of bypass surgery has declined by 43%, while the rate of endovascular treatments has climbed by orders of magnitude. Asia Pacific is expected to expand the quickest in the future years. This is due to increased knowledge of cardiac disorders, improved neonatal screening programmes, and improved healthcare access.


Major market player included in this report are:
Boston Scientific Corporation
Medtronic
Edwards Lifesciences Corporation
Abbott Laboratories
ST. JUDE MEDICAL
Biomerics,
Comed BV
LivaNova PLC
JenaValve Technology Inc.,
CardioKinetix
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Type:
Surgical Aortic Valve Replacement
Transcatheter Aortic Valve Replacement
Mitral Repair
Left Atrial Appendage Closure
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028

Target Audience of the Global Structural Heart Devices Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors

Companies Mentioned

Boston Scientific Corporation
Medtronic
Edwards Lifesciences Corporation
Abbott Laboratories
ST. JUDE MEDICAL
Biomerics,
Comed BV
LivaNova PLC
JenaValve Technology Inc.,
CardioKinetix

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.